Medications for Acute Coronary Syndromes
KEYWORDS: patients, orally, risk, heparin, pci, day, used, hours, bleeding, given, nitroglycerin, therapy, coronary, use, acs

be reduced to < 110 to 120 mm Hg systolic; patients who remain symptomatic at that BP should have emergency PCI rather than further BP reduction. Longer use may benefit patients with recurrent chest pain or persistent pulmonary congestion. In high- risk patients, nitroglycerin given in the first few hours reduces infarct size and short-term and possibly long-term mortality risk. Nitroglycerin is not routinely given to low-risk patients with uncomplicated myocardial infarction. Fibrinolytics Tenecteplase (TNK), alteplase (rTPA), reteplase (rPA), streptokinase, and anistreplase (anisoylated plasminogen activator complexâ€”APSAC), all given IV, are plasminogen activators. They convert single- chain plasminogen to double-chain plasminogen, which has fibrinolytic activity. They have different characteristics and dosing regimens (see table IV Fibrinolytic Therapies) and are appropriate only for selected patients with STEMI). Tenecteplase and reteplase are recommended most often because of their simplicity of administration; tenecteplase is given as a single bolus over 5 seconds and reteplase as a double bolus 30 minutes apart. Administration time and medication errors are reduced compared with other fibrinolytics. Tenecteplase, like alteplase, has an intermediate risk of intracranial hemorrhage and has a higher rate of recanalization than other fibrinolytics. Reteplase has the highest risk of intracranial hemorrhage and a recanalization rate
